INTRODUCTION {#s1}
============

Peripheral arterial diseases include a collection of occlusive and aneurysmal diseases affecting arteries outside the heart estimated to affect approximately 5% of adults \[[@R1]\]. The mechanisms responsible for ischemic complications of peripheral artery atherosclerosis are believed to be similar to those implicated in coronary atherosclerosis \[[@R2]\]. In keeping with the perceived similar pathogenesis of coronary and peripheral artery disease most of the drug therapies used in patients with these conditions are the same \[[@R3]\]. The mechanisms involved in abdominal aortic aneurysm (AAA) development and their relationship with atherosclerosis are however controversial \[[@R4]\]. Examination of human AAA biopsies has consistently identified concurrent intimal atherosclerosis and most AAAs have been considered to result from atherosclerosis \[[@R5], [@R6]\]. Some of the risk factors for atherosclerosis and AAA are however distinct, for example diabetes an important positive risk factor for occlusive artery disease is a negative risk factor for AAA \[[@R4], [@R5]\]. Dyslipidemia is also believed to be a less important risk factor for AAA than atherosclerotic occlusive disease \[[@R7]\]. There are also a number of similarities between atherosclerosis and AAA, including common risk factors of smoking, hypertension, and male gender \[[@R5], [@R8], [@R9]\]. The role of atherosclerosis in AAA therefore is currently controversial \[[@R4]\].

Examination of mechanisms involved in AAA has mainly relied on use of animal, particularly rodent, models \[[@R10]\]. The availability of whole genome expression profiling has allowed insight into a range of human pathologies but has been relatively sparingly applied to AAA and aortic atherosclerosis \[[@R11]-[@R15]\]. Two previous studies have examined the whole genome expression profile of human AAA specimen although sample sizes for these studies were relatively small totaling 7 and 10 AAA patients, and no comparison was performed with atherosclerosis \[[@R11], [@R12]\]. In the current study we examined the whole genome expression profiles of a relatively large number of human aortic biopsies from subjects undergoing surgery to repair AAAs and to treat chronic lower limb ischemic due to aortic atherosclerosis (aortic occlusive disease, AOD). Aortic wall samples obtained from organ donors were used as controls. We aimed to compare the aortic gene expression profile of patients with AAA and AOD to those of older subjects with normal aortic histology.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

The gene expression was initially assessed in the aortic biopsies of 20 patients with small AAAs (mean AAA diameter 53.4±2.3 mm), 29 patients with large AAAs (mean AAA diameter 68.4±14.3 mm), 9 patients with AOD (mean aortic diameter 19.6±2.6 mm), and 10 control organ donors using microarrays (Table [1](#T1){ref-type="table"}). AAA patients were less likely to be female compared to controls (small AAA 0%, large AAA 7%, controls 40%; *P* \< 0.05), while AOD patients were younger compared to controls (mean age 61.6±9.3 *vs*. 68.4±4.5 years, *P* \< 0.05). The validity of microarray findings was further assessed in biopsies obtained from 6 patients with small AAAs, 9 patients with large AAAs, 8 AOD patients, and 6 controls (Table [1](#T1){ref-type="table"}). AAA and AOD cases were older compared to controls (mean age small AAAs 69.7±3.8, large AAAs 71.5±7.8, AOD 67.8±4.2, controls 42.7±12.5 years; *P* \< 0.05). Mean maximum AAA diameter was 48.5±5.7 and 65.9±7.3 mm in patients with small and large AAAs, respectively.

###### Characteristics of subjects included in this study

  Characteristic           Discovery group                             Validation group                                                                                                                                                                                                                               
  ------------------------ ------------------------------------------- ------------------------------------------- --------------------------------------------- ---------- --------------------------------------------- --------------------------------------------- --------------------------------------------- -----------
  Number                   20                                          29                                          9                                             10         6                                             9                                             8                                             6
  Aortic diameter (mm)     53.4±2.3                                    68.4±14.3                                   19.6±2.6                                      25.7±1.2   48.5±5.7                                      65.9±7.3                                      \-                                            \-
  Women                    [\*](#tfn_001){ref-type="table-fn"}0 (0%)   [\*](#tfn_001){ref-type="table-fn"}2 (7%)   1 (11%)                                       4 (40%)    1 (17%)                                       2 (22%)                                       2 (25%)                                       2 (33%)
  Age (years)              68.8±6.9                                    70.5±7.1                                    [\*](#tfn_001){ref-type="table-fn"}61.6±9.3   68.4±4.5   [\*](#tfn_001){ref-type="table-fn"}69.7±3.8   [\*](#tfn_001){ref-type="table-fn"}71.5±7.8   [\*](#tfn_001){ref-type="table-fn"}67.8±4.2   42.7±12.5
  PAD                      3 (15%)                                     5 (17%)                                     9 (100%)                                      \-         0 (0%)                                        0 (0%)                                        8 (100%)                                      \-
  Hypertension             15 (75%)                                    25 (86%)                                    8 (89%)                                       \-         4 (67%)                                       6 (67%)                                       7 (88%)                                       \-
  Diabetes mellitus        4 (20%)                                     7 (24%)                                     1 (11%)                                       \-         4 (67%)                                       1 (11%)                                       1 (13%)                                       \-
  Dyslipidemia             15 (75%)                                    20 (69%)                                    8 (89%)                                       \-         6 (100%)                                      5 (56%)                                       6 (75%)                                       \-
  Coronary heart disease   8 (40 %)                                    17 (59%)                                    7 (78%)                                       \-         4 (67%)                                       5 (56%)                                       4 (50%)                                       \-
  Ever smoker              7 (35%)                                     21 (72%)                                    9 (100%)                                      5 (50%)    4 (67%)                                       6 (67%)                                       8 (100%)                                      \-
  BMI (kg/m^2^)            28.8±3.2                                    26.8±4.0                                    23.7±2.4                                      22.7±9.6   34.0±5.5                                      25.3±3.6                                      21.9±4.1                                      \-

AAA, abdominal aortic aneurysm; AOD, aortic occlusive disease; BMI, body mass index. Nominal variables are presented as numbers; continuous variables are presented as mean ± standard deviation. AAA or AOD were compared with controls. Continuous variables were compared using Mann Whitney U test; nominal variables were compared using Fisher\'s exact test

Asterisk indicates statistically significant differences compared to the control group (*P* \< 0.05).

Numerical assessment of gene expression profiles in small AAAs, large AAAs, and AOD {#s2_2}
-----------------------------------------------------------------------------------

A total of 39,157 transcripts in small AAAs, 39,389 transcripts in large AAAs, 37,904 transcripts in AOD, and 36,725 transcripts in control samples, representing \> 80% of the Illumina HumanHT-12 v4 Expression BeadChip reference list, were expressed above background and subjected to differential gene expression analysis. A total of 840 individual genes were differentially expressed (≥ 2.0-fold, adjusted *P* \< 0.05) in small AAAs compared to controls (122 upregulated and 718 downregulated genes; Figure [1a and 1b](#F1){ref-type="fig"}, respectively). A total of 1,014 individual genes were differentially expressed (≥ 2.0 fold, adjusted *P* \< 0.05) in large AAAs compared to controls (215 upregulated and 799 downregulated genes; Figure [1a and 1b](#F1){ref-type="fig"}, respectively). 1,765 individual genes were differentially expressed (≥ 2.0-fold, adjusted *P* \< 0.05) in AOD compare to controls (1,677 upregulated and 88 downregulated genes; Figure [1a and 1b](#F1){ref-type="fig"}, respectively). Full lists of differentially expressed genes are given in [Supplemental Table I](#SD1){ref-type="supplementary-material"}, [Supplemental Table II](#SD2){ref-type="supplementary-material"}, and [Supplemental Table III](#SD3){ref-type="supplementary-material"} for small AAA, large AAA, and AOD, respectively. A preponderance of genes upregulated in small AAAs (100/122; 82%) were also upregulated in large AAAs. Approximately 47% (100/215; Figure [1a](#F1){ref-type="fig"}) of the genes upregulated in large AAAs were also upregulated in small AAAs. In contrast only one gene (*CXCL12*) differentially expressed in AOD samples (1/1,765) was also differentially expressed in small (1/840) or large (1/1,014) AAAs (Figure [1a and 1b](#F1){ref-type="fig"}).

![Distribution of differentially expressed genes in aortic aneurysmal and occlusive disease\
Venn diagrams depict the overlap among differentially expressed genes in patients with small and large abdominal aortic aneurysm (AAA) and aortic occlusive disease (AOD). Shown are a number of upregulated (**a**) and downregulated (**b**) genes. Patients with small or large AAA or AOD were compared with patients without AAA (Controls), (\> 2-fold difference, *P* value \< 0.05 calculated with non-parametric Mann-Whitney test and corrected by Benjamini and Hochberg method).](oncotarget-06-12984-g001){#F1}

Pathways related to the differentially expressed genes in small and large AAA {#s2_3}
-----------------------------------------------------------------------------

We performed an enrichment analysis of differentially expressed genes with particular attention to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways to assess the biological contexts of these genes. KEGG annotations included 93% (114/122) of upregulated genes and 92% (661/718) of downregulated genes in small AAAs; and 91% (196/215) of upregulated genes and 95% (756/799) of downregulated genes in large AAA samples. The KEGG analysis revealed marked upregulation of genes related to immune responses in both small and large AAA. These pathways included cytokine-cytokine receptor interaction (hsa04060; *P* = 1.15\*10^−14^ for small AAA, and *P* = 2.52\*10^−17^ for large AAA), chemokine signaling pathway (hsa04062; *P* = 4.50\*10^−11^ for small AAA, and *P* = 3.53\*10^−12^ for large AAA), and T-cell receptor signaling pathway (hsa04660; *P* = 4.07\*10^−05^ for small AAA, and *P* = 2.40\*10^−06^ for large AAA) as shown in Table [2](#T2){ref-type="table"}. Metabolic pathways (hsa01100) and oxidative phosphorylation (hsa00190) were found among the top 10 most significant KEGG categories enriched by downregulated genes with *P* = 2.30\*10^−22^ (metabolic pathways) and *P* = 4.25\*10^−20^ (oxidative phosphorylation) for small AAA; and *P* = 1.05\*10^−24^ (metabolic pathways) and *P* = 8.60\*10^−20^ (oxidative phosphorylation) for large AAA (Table [2](#T2){ref-type="table"}).

###### Top 10 KEGG pathways enriched in small and large abdominal aortic aneurysm

  Category                                          Pathway                                  KEGG       N      n               P value
  ------------------------------------------------- ---------------------------------------- ---------- ------ --------------- ---------------
  Small AAA-upregulated genes                       Cytokine-cytokine receptor interaction   hsa04060   267    15              1.15\*10^−14^
  Chemokine signaling pathway                       hsa04062                                 190        11     4.50\*10^−11^   
  Hematopoietic cell lineage                        hsa04640                                 88         7      3.68\*10^−08^   
  NOD-like receptor signaling pathway               hsa04621                                 62         6      1.18\*10^−07^   
  Cell adhesion molecules (CAMs)                    hsa04514                                 134        7      4.15\*10^−07^   
  Jak-STAT signaling pathway                        hsa04630                                 155        7      9.36\*10^−07^   
  Intestinal immune network for IgA production      hsa04672                                 50         4      4.07\*10^−05^   
  T cell receptor signaling pathway                 hsa04660                                 108        5      4.07\*10^−05^   
  Cytosolic DNA-sensing pathway                     hsa04623                                 56         4      5.46\*10^−05^   
  Pathways in cancer                                hsa05200                                 330        7      8.39\*10^−05^   
  Small AAA-downregulated genes                     Ribosome                                 hsa03010   88     27              2.50\*10^−26^
  Metabolic pathways                                hsa01100                                 1104       69     2.30\*10^−22^   
  Oxidative phosphorylation                         hsa00190                                 135        26     4.25\*10^−20^   
  Parkinson\'s disease                              hsa05012                                 133        25     3.60\*10^−19^   
  Alzheimer\'s disease                              hsa05010                                 169        27     6.00\*10^−19^   
  Huntington\'s disease                             hsa05016                                 185        28     6.00\*10^−19^   
  Focal adhesion                                    hsa04510                                 201        23     5.48\*10^−13^   
  Cardiac muscle contraction                        hsa04260                                 79         15     7.66\*10^−12^   
  Arrhythmogenic right ventricular cardiomyopathy   hsa05412                                 76         11     1.65\*10^−07^   
  Vascular smooth muscle contraction                hsa04270                                 115        13     1.65\*10^−07^   
  Large AAA-upregulated genes                       Cytokine-cytokine receptor interaction   hsa04060   267    20              2.52\*10^−17^
  Chemokine signaling pathway                       hsa04062                                 190        14     3.53\*10^−12^   
  Hematopoietic cell lineage                        hsa04640                                 88         10     9.95\*10^−11^   
  Primary immunodeficiency                          hsa05340                                 35         7      1.89\*10^−09^   
  Cell adhesion molecules (CAMs)                    hsa04514                                 134        9      7.87\*10^−08^   
  Intestinal immune network for IgA production      hsa04672                                 50         6      6.70\*10^−07^   
  Cytosolic DNA-sensing pathway                     hsa04623                                 56         6      1.15\*10^−06^   
  NOD-like receptor signaling pathway               hsa04621                                 62         6      1.86\*10^−06^   
  Jak-STAT signaling pathway                        hsa04630                                 155        8      2.30\*10^−06^   
  T cell receptor signaling pathway                 hsa04660                                 108        7      2.40\*10^−06^   
  Large AAA-downregulated genes                     Metabolic pathways                       hsa01100   1104   78              1.05\*10^−24^
  Huntington\'s disease                             hsa05016                                 185        31     3.64\*10^−20^   
  Oxidative phosphorylation                         hsa00190                                 135        27     8.60\*10^−20^   
  Alzheimer\'s disease                              hsa05010                                 169        28     2.45\*10^−18^   
  Parkinson\'s disease                              hsa05012                                 133        25     7.70\*10^−18^   
  Ribosome                                          hsa03010                                 88         18     1.32\*10^−13^   
  Cardiac muscle contraction                        hsa04260                                 79         16     4.25\*10^−12^   
  Focal adhesion                                    hsa04510                                 201        23     8.41\*10^−12^   
  Vascular smooth muscle contraction                hsa04270                                 115        17     1.27\*10^−10^   
  Fatty acid metabolism                             hsa00071                                 42         10     1.70\*10^−08^   

AAA, abdominal aortic aneurysm; N, number of reference genes in the pathway; n, number of genes differentially expressed in pathway in small or large AAA compared to patients without AAA (Controls); \> 2-fold difference, P value \< 0.05 calculated with non-parametric Mann-Whitney test and corrected by Benjamini and Hochberg method. P value indicates the corrected significance of enrichment calculated from the hypergeometric test by Benjamini and Hochberg method. Pathways were identified using WebGestalt and were linked to the KEGG (Kyoto Encyclopedia of Genes and Genomes) website <http://www.genome.jp/kegg/>.

Differentially expressed genes in small and large AAA {#s2_4}
-----------------------------------------------------

Considering the marked enrichment of immune response categories in small and large AAA, we further examined a number of genes related to the immune response (Table [3](#T3){ref-type="table"}). A majority of genes upregulated in small AAA were also upregulated in large AAA. Examples include genes coding for: pro-inflammatory cytokines *IL1B* (5.08-fold, *P* = 0.002 for small AAA; 3.85-fold, *P* = 0.001 for large AAA), *IL6* (6.28-fold, *P* = 0.004 for small AAA; 6.48-fold, *P* = 0.002 for large AAA), and *IL8* (4.49-fold, *P* = 0.005 for small AAA; 3.65-fold, *P* = 0.004 for large AAA); chemokines *CXCL2* (3.35-fold, *P* = 0.004 for small AAA; 2.73-fold, *P* = 0.005 for large AAA), *CXCL13* (2.21-fold, *P* = 0.013 for small AAA; 3.09-fold, *P* = 0.002 for large AAA), *CCL3L3* (3.14-fold, *P* = 0.039 for small AAA; 2.59-fold, *P* = 0.041 for large AAA), and *CCL4L2* (2.48-fold, *P* = 0.021 for small AAA; 2.12-fold, *P* = 0.023 for large AAA); early T-cell and B-cell activation cluster of differentiation (CD) antigens *CD69* (2.67-fold, *P* = 0.039 for small AAA; 3.45-fold, *P* = 0.004 for large AAA) and *CD19* (2.79-fold, *P* = 0.026 for small AAA; 4.45-fold, *P* = 0.002 for large AAA), respectively; and the natural killer (NK) cells associated protein *NKTR* (2.37-fold, *P* = 0.002 for small AAA; 2.66-fold, *P* = 0.001 for large AAA). An important negative regulator of T-cells responses, the *CTLA4* gene, was exclusively upregulated in small AAA (2.01-fold, *P* = 0.018). On the other hand, there was increased expression of genes related to T-cell and B-cell responses exclusively in large AAA, including alpha chain of the T-cell co-receptor *CD8A* (2.24-fold, *P* = 0.012); the *CD79A*/*CD79B* membrane-bound dimer immunoglobulin in B-cells (2.76-fold, *P* = 0.005/3.43-fold, *P* = 0.004); the receptors for Fc fragment of IgG in B-cells *FCRL2* (2.53-fold, *P* = 0.002), *FCRL5* (2.01-fold, *P* = 0.001), and *FCRLA* (3.15-fold, *P* = 0.009). Three genes (*CTLA4*, *NKTR*, and *CD8A*) were selected for further validation with quantitative real-time PCR.

###### Examples of differentially expressed genes in small and large AAA with some connection to immunity

  Symbol     Name                                             Small AAA   Large AAA          
  ---------- ------------------------------------------------ ----------- ----------- ------ -------
  *IL1B*     interleukin 1, beta                              5.08        0.002       3.85   0.001
  *IL6*      interleukin 6                                    6.28        0.004       6.48   0.002
  *IL8*      interleukin 8                                    4.49        0.005       3.65   0.004
  *CXCL2*    chemokine (C-X-C motif) ligand 2                 3.35        0.004       2.73   0.005
  *CXCL13*   chemokine (C-X-C motif) ligand 13                2.21        0.013       3.09   0.002
  *CCL3L3*   chemokine (C-C motif) ligand 3-like 3            3.14        0.039       2.59   0.041
  *CCL4L2*   chemokine (C-C motif) ligand 4-like 2            2.48        0.021       2.12   0.023
  *CD69*     CD69 molecule                                    2.67        0.039       3.45   0.004
  *CD19*     CD19 antigen                                     2.79        0.026       4.45   0.002
  *NKTR*     natural killer-tumor recognition sequence        2.37        0.002       2.66   0.001
  *CTLA4*    cytotoxic T-lymphocyte-associated protein 4      2.01        0.018       \-     \-
  *CD8A*     CD8 antigen, alpha chain                         \-          \-          2.24   0.012
  *CD79A*    CD79A antigen, immunoglobulin-associated alpha   \-          \-          2.76   0.005
  *CD79B*    CD79b molecule, immunoglobulin-associated beta   \-          \-          3.43   0.004
  *FCRL2*    Fc receptor-like 2                               \-          \-          2.53   0.002
  *FCRL5*    Fc receptor-like 5                               \-          \-          2.01   0.001
  *FCRLA*    Fc receptor-like A                               \-          \-          3.15   0.009

AAA, abdominal aortic aneurysm. Differentially expressed genes were determined by comparison of patients with small or large AAA with patients without AAA (Controls), (\> 2-fold change, P value \< 0.05 calculated with non-parametric Mann-Whitney test and corrected by Benjamini and Hochberg method).

Pathways related to the differentially expressed genes in AOD {#s2_5}
-------------------------------------------------------------

92% (1,550/1,677) of upregulated genes and 90% (79/88) of downregulated genes in AOD samples were annotated in the KEGG pathways. The pathways enriched in AOD samples were distinct to those identified in AAA samples. In AOD, the most significant KEGG categories representing upregulated genes were metabolic pathways (hsa01100; *P* = 1.49\*10^−43^) and oxidative phosphorylation (hsa00190; *P* = 5.68\*10^−35^). Downregulated genes primarily fell into the immune response categories such as cytokine-cytokine receptor interaction (hsa04060; *P* = 5.69^−07^) and chemokine signaling pathways (hsa04062; *P* = 8.64\*10^−06^) as seen in Table [4](#T4){ref-type="table"}.

###### Top 10 KEGG pathways enriched in aortic occlusive disease

  Category                                Pathway                                  KEGG       N      n               P value
  --------------------------------------- ---------------------------------------- ---------- ------ --------------- ---------------
  AOD-upregulated genes                   Metabolic pathways                       hsa01100   1104   147             1.49\*10^−43^
  Oxidative phosphorylation               hsa00190                                 135        49     5.68\*10^−35^   
  Parkinson\'s disease                    hsa05012                                 133        46     7.03\*10^−32^   
  Huntington\'s disease                   hsa05016                                 185        52     4.11\*10^−31^   
  Alzheimer\'s disease                    hsa05010                                 169        48     5.02\*10^−29^   
  Ribosome                                hsa03010                                 88         35     6.28\*10^−27^   
  Focal adhesion                          hsa04510                                 201        38     1.90\*10^−16^   
  Spliceosome                             hsa03040                                 128        29     8.16\*10^−15^   
  Cardiac muscle contraction              hsa04260                                 79         21     2.63\*10^−12^   
  Proteasome                              hsa03050                                 48         17     2.63\*10^−12^   
  AOD-downregulated genes                 Cytokine-cytokine receptor interaction   hsa04060   267    8               5.69\*10^−07^
  Hematopoietic cell lineage              hsa04640                                 88         5      5.93\*10^−06^   
  Chemokine signaling pathway             hsa04062                                 190        6      8.64\*10^−06^   
  Regulation of actin cytoskeleton        hsa04810                                 216        5      2.00\*10^−04^   
  Graft-versus-host disease               hsa05332                                 42         3      3.00\*10^−04^   
  Jak-STAT signaling pathway              hsa04630                                 155        4      6.00\*10^−04^   
  Pathogenic Escherichia coli infection   hsa05130                                 59         3      6.00\*10^−04^   
  NOD-like receptor signaling pathway     hsa04621                                 62         3      6.00\*10^−04^   
  Toll-like receptor signaling pathway    hsa04620                                 101        3      2.10\*10^−04^   
  Prion diseases                          hsa05020                                 35         2      3.70\*10^−04^   

AOD, aortic occlusive disease; N, number of reference genes in the pathway; n, number of genes differentially expressed in pathway in AOD compared to patients without AAA (Controls); \> 2-fold difference, P value \< 0.05 calculated with non-parametric Mann-Whitney test and corrected by Benjamini and Hochberg method. P value indicates the corrected significance of enrichment calculated from the hypergeometric test by Benjamini and Hochberg method. Pathways were identified using WebGestalt and were linked to the KEGG (Kyoto Encyclopedia of Genes and Genomes) website <http://www.genome.jp/kegg/>.

Differentially expressed genes in AOD {#s2_6}
-------------------------------------

Inspection of genes within KEGG metabolic categories revealed upregulation of genes related to mitochondrial biogenesis that included many members of all five mitochondrial respiratory and ATP production complexes (Table [5](#T5){ref-type="table"}). We also demonstrated the upregulation of numerous genes involved in glycolysis/gluconeogenesis, fatty acid metabolism, and propanoate metabolism (Table [5](#T5){ref-type="table"}). Several complement system genes were overexpressed such as *C1S* (2.08-fold, *P* = 0.044), *CD46* (2.00-fold, *P* = 0.004), *CFH* (2.81-fold, *P* = 0.006), *CFI* (2.02-fold, *P* = 0.004), *C1QBP* (2.10-fold, *P* = 0.003), *C1RL* (2.08-fold, *P* = 0.003), and *C7* (3.46-fold, *P* = 0.037). One important mitochondrial regulatory gene called mitochondrial uncoupling protein 2 (*UCP2*) was downregulated in AOD samples (−3.73-fold, *P* = 0.014), (Table [5](#T5){ref-type="table"}). The *UCP2* gene was selected for further validation with quantitative real-time PCR.

###### Examples of differentially expressed genes in AOD

  Symbol      Name                                                                           Function      Fold change   Corrected P value
  ----------- ------------------------------------------------------------------------------ ------------- ------------- -------------------
  *NDUFA3*    NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3                          Complex I     2.71          0.003
  *NDUFB3*    NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3                           Complex I     2.53          0.003
  *NDUFA7*    NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7                          Complex I     2.12          0.003
  *NDUFB6*    NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6                           Complex I     2.68          0.003
  *SDHA*      succinate dehydrogenase complex, subunit A                                     Complex II    2.00          0.003
  *SDHD*      succinate dehydrogenase complex, subunit D                                     Complex II    2.66          0.003
  *UQCRB*     ubiquinol-cytochrome c reductase binding protein                               Comples III   2.89          0.003
  *UQCRH*     ubiquinol-cytochrome c reductase hinge protein                                 Comples III   10.76         0.003
  *UQCRFS1*   ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1             Comples III   2.62          0.003
  *COX5B*     cytochrome c oxidase subunit Vb                                                Complex IV    4.62          0.003
  *COX6A1*    cytochrome c oxidase subunit VIa polypeptide 1                                 Complex IV    2.06          0.008
  *COX6B1*    cytochrome c oxidase subunit VIb polypeptide 1                                 Complex IV    10.45         0.003
  *COX6C*     cytochrome c oxidase subunit VIc                                               Complex IV    3.34          0.003
  *COX7C*     cytochrome c oxidase subunit VIIc                                              Complex V     4.32          0.003
  *ATP5C1*    ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1   Complex V     2.22          0.003
  *ATP5D*     ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit         Complex V     2.00          0.005
  *ATP5J*     ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F6            Complex V     3.13          0.003
  *UCP2*      uncoupling protein 2                                                           Uncoupling    −3.73         0.014
  *ALDH1B1*   aldehyde dehydrogenase 1 family, member B1                                     G/F/P         2.84          0.008
  *ALDH2*     aldehyde dehydrogenase 2 family                                                G/F/P         2.03          0.017
  *ALDH3A2*   aldehyde dehydrogenase 3 family, member A2                                     G/F/P         2.45          0.003
  *ALDH9A1*   aldehyde dehydrogenase 9 family, member A1                                     G/F/P         2.61          0.003
  *PDHB*      pyruvate dehydrogenase beta                                                    G             2.64          0.003
  *TPI1*      triosephosphate isomerase 1                                                    G             2.23          0.003
  *ACADL*     acyl-CoA dehydrogenase, long chain                                             F             2.04          0.003
  *ACAT1*     acetyl-CoA acetyltransferase 1                                                 F             3.81          0.003
  *MCEE*      methylmalonyl CoA epimerase                                                    P             2.34          0.003
  *MUT*       methylmalonyl CoA mutase                                                       P             2.08          0.003
  *C1S*       complement component 1, s subcomponent                                         Complement    2.08          0.044
  *CD46*      CD46 molecule                                                                  Complement    2.00          0.004
  *CFH*       complement factor H                                                            Complement    2.81          0.006
  *CFI*       complement factor I                                                            Complement    2.02          0.004
  *C1QBP*     complement component 1, q subcomponent binding protein                         Complement    2.10          0.003
  *C1RL*      complement component 1, r subcomponent-like                                    Complement    2.08          0.003
  C7          complement component 7                                                         Complement    3.46          0.037

G, Glycolysis/Gluconeogenesis; F, Fatty acid metabolism; P, Propanoate metabolism; Complex I --V, mitochondrial complexes. Differentially expressed genes were determined by comparisons of patients of aortic occlusive disease (AOD) with patients without AAA (Controls), (\> 2-fold change, corrected P value \< 0.05 calculated with non-parametric Mann-Whitney test and corrected by Benjamini and Hochberg method.

Real time PCR {#s2_7}
-------------

Expression levels of a number of genes were validated in biopsies from the six patients with small AAAs, nine patients with large AAAs, eight patients with AOD and six controls (Table [1](#T1){ref-type="table"}). The relative expression of *CTLA4* was significantly increased in small AAA but not large AAA biopsies compared to normal controls (Table [6](#T6){ref-type="table"}). Median relative expression of *CTLA4* was also markedly increased in small AAA versus large AAA biopsies (202.161 vs. 65.239, P = 0.041). The relative expression of *CD8A* was significantly increased in large AAA but not small AAA biopsies compared to normal controls (Table [6](#T6){ref-type="table"}), with the median relative expression of *CD8A* in large AAA \~2-fold higher and approaching significance compared to small AAA (109.489 *vs* 61.004; *P* = 0.065). Correspondingly, immunohistochemical examination of AAA tissue demonstrated marked presence of CD8-positive T lymphocytes within the adventitia and outer media of a large (82mm) AAA (Figure [2A](#F2){ref-type="fig"}) with limited immunostaining for CTLA4 (Figure [2C](#F2){ref-type="fig"}). In contrast there was relatively sparse presence of CD8-positive T cells within tissue from a small (55mm) AAA (Figure [2B](#F2){ref-type="fig"}) but marked CTLA4 staining around tertiary lymphoid tissue at the media-adventia border (Figure [2D](#F2){ref-type="fig"}).

###### Validation of genes differentially expressed in AAA or AOD by qRT-PCR

  Gene             Sample      N         Median            IQR               Fold change   P
  ---------------- ----------- --------- ----------------- ----------------- ------------- -------
  *CTLA4*          Small AAA   6         202.161           120.109-376.825   11.12         0.002
  Normal control   6           18.185    10.526-24.477                                     
  Large AAA        9           65.239    17.268-176.354    3.59              0.065         
  Normal control   6           18.185    10.526-24.477                                     
  Small AAA        6           202.161   120.109-376.825   3.10              0.041         
  Large AAA        9           65.239    17.268-176.354                                    
  *CD8A*           Small AAA   6         61.004            51.980-69.598     1.60          0.132
  Normal control   6           38.194    18.075-46.661                                     
  Large AAA        9           109.487   61.730-176.194    2.87              0.004         
  Normal control   6           38.194    18.075-46.661                                     
  Small AAA        6           61.004    51.980-69.598     −1.79             0.065         
  Large AAA        9           109.487   61.730-176.194                                    
  *NKTR*           Small AAA   6         0.651             0.349-0.695       1.66          0.041
  Normal control   6           0.391     0.381-0.404                                       
  Large AAA        9           1.186     0.771-1.923       3.03              0.015         
  Normal control   6           0.391     0.381-0.404                                       
  Small AAA        6           0.651     0.349-0.695       −1.82             0.040         
  Large AAA        9           1.186     0.771-1.923                                       
  *UCP2*           AOD         8         0.729             0.545-0.737       −3.16         0.017
  Normal control   6           2.306     0.909-5.070                                       

AAA, abdominal aortic aneurysm; AOD, aortic occlusive disease; N, number of samples; Median, median gene expression relative to reference gene (*ACTB*); IQR, interquartile range; P, two-sided P value by Mann-Whitney U test.

![CD8+ lymphocytes and CTLA4 in large versus small AAA\
Immunohistochemical staining identifying the increased presence of CD8+ T cells (brown stain) in tissue from large AAA (**A**) versus small AAA (**B**) associated with lower detection of CTLA4 (red stain) in large (**C**) compared to small AAA (**D**); scale bar = 50 μm (A & B) & 100 μm (**C** & **D**).](oncotarget-06-12984-g002){#F2}

Median relative expression of *NKTR* was significantly greater in AAA biopsies compared to normal controls with approximately 2- (*P* = 0.041) and 3- (*P* = 0.015) fold increase for small and large AAAs, respectively (Table [6](#T6){ref-type="table"}). Median relative expression of *NKTR* was also markedly increased in large AAA compared to small AAA biopsies (1.186 vs. 0.651, *P* = 0.040).

The relative expression of *UCP2* was markedly decreased in AOD samples compared to normal controls (Table [6](#T6){ref-type="table"}). In subjects with AOD the *UCP2* mRNA expression was more than 3-fold lower compared to the control aortic biopsies (0.739 *vs*. 2.306, *P* = 0.017).

DISCUSSION {#s3}
==========

Human AAA biopsies have been consistently shown to have intimal atheroma and historically AAAs have been considered to result from atherosclerosis \[[@R5], [@R6]\]. However the mechanisms involved in AAA development and its relationship with atherosclerosis remain controversial \[[@R4]\]. We determined the global gene expression profiles within biopsies of AAA and AOD using microarrays. The main finding from this study was that the genes differentially expressed in AAA and AOD were almost completely distinct, supporting the concept of separate developmental mechanisms underlying the pathogenesis of each disease \[[@R4]\]. With this in mind, global gene expression profiles associated with AAA and AOD will be further discussed separately.

AAA {#s3_1}
---

A number of human and animal studies previously suggested a major role of immune responses in AAA pathogenesis \[[@R11]-[@R15]\] and the array findings for cytokines/chemokines are in line with previous quantitative data \[[@R18]\]. Our results substantiate those findings, and more importantly, suggest also that small AAAs (≤ 55 mm) and large AAAs (\> 55 mm) may have some distinct immunological characteristics. The most notable finding related to immunity was that the key T-cell regulatory gene called cytotoxic T-lymphocyte-associated protein 4 (*CTLA4* or *CD152*) was exclusively found to be upregulated in small AAAs. Moreover, our data suggests excessive infiltration of CD8^+^ T-cells in biopsies from large AAAs evidenced by the exclusive overexpression of the gene coding for the CD8A molecule and increased number of CD8+ T-cells found in these specimens. The upregulation of *CTLA4* and *CD8A* in small AAA and large AAA, respectively, was confirmed by qRT-PCR and led us to hypothesize that downregulation of *CTLA4* may represent a key mechanism in AAA progression which promotes excessive T-cell-driven immune responses in large AAAs. This hypothesis is supported by our finding of marked downregulation of the *CTLA4* mRNA and the protein product in large AAAs compared to small AAAs as determined by qRT-PCR and immunohistochemistry, respectively. CTLA4 is a cell surface molecule that can down-modulate and terminate T-cell adaptive immunity \[[@R19]\]. The CD8A molecule is a constituent of the CD8 antigen found on most cytotoxic T lymphocytes and acts as a co-receptor with the T-cell receptor (TCR). Previous immunohistochemical studies of human AAA have provided evidence that CD8^+^ T-cells infiltrating the aortic wall express cytotoxic mediators such as perforins, which generate membrane damage \[[@R20]\]. Other studies have shown that immunosuppressive agents directed exclusively at T-cells are capable of reducing the expansion of experimental AAA \[[@R21]\] and reduce vascular inflammation and aortic wall content of several inflammatory cell types including cytotoxic T lymphocytes in human AAA \[[@R22]\]. Taken together, the manipulation of CTLA4 levels may represent a novel therapeutic strategy for AAAs but this need examining in other contexts e.g. animal models. The use of CTLA4-based biologic agents such as Abatacept (Orencia), a novel fusion protein of the Fc region of the immunoglobulin IgG1 and CTLA4 designed to down-regulate T-cells activity, is already under investigation as a potential therapy for other immunopathologies such as active rheumatoid arthritis \[[@R23]-[@R27]\]. Findings from the present study additionally demonstrate the upregulation of genes expressed by NK cells within large AAAs, such as natural killer cell group 7 sequence (*NKG7*) and natural killer-tumor recognition sequence (*NKTR*) genes; both involved in the TCR-independent innate immune responses. The latter was assessed and validated to be upregulated in large AAAs by qRT-PCR. It is possible that similar mechanisms involving the upregulation of innate immunity occur at some point between the late and end-stage of AAA. Findings suggest marked upregulation of the *NKTR* gene in large AAA compared to small AAA biopsies which is in accord with this hypothesis.

AOD {#s3_2}
---

Genes differentially expressed in AOD versus control samples were particularly related to the metabolic and oxidative phosphorylation pathways which accounted for \~12% of all upregulated genes. In particular, we determined the excessive transcription of genes involved in mitochondrial biogenesis affecting numerous members of all four mitochondrial respiratory complexes as well as genes responsible for ATP synthesis in the mitochondrial complex V. Other pathways enriched included those related to Parkinson\'s disease. Genes involved in this category belonging to the mitochondrial complex I were upregulated in AOD, contrasting the actual disruption of the mitochondrial complex I in Parkinson\'s disease itself \[[@R28]\]. We also demonstrated the upregulation of a range of genes involved in glycolysis, gluconeogenesis, fatty acid metabolism, and propanoate metabolism. Since the number of overlapping genes in these metabolic pathways is considerable, it would be reasonable to suggest that overexpression of these genes may simply represent a metabolic maladaptation to the excessive mitochondrial biogenesis, as members of these bioenergetic pathways are tightly coordinated transcriptionally \[[@R29]-[@R31]\]. Upregulation of genes related to glucose and fatty acids metabolism is highly relevant to AOD. The role of an impaired glucose tolerance and fatty acids metabolism in atherosclerosis is long-documented \[[@R32], [@R33]\]. Current evidence suggests that the ataxia telangiectasia mutated (ATM)/mammalian target of rapamycin (mTOR) signaling axis may play an important role in suppression of macrophage transformation into foam cells, thus limiting the formation of atherosclerotic plaques \[[@R34]\]. Interestingly, the old malaria drug Chloroquine (Aralen), a lysosomotropic agent that activates ATM signaling, was found to be capable of decreasing atherosclerosis and improving metabolic phenotype in mice \[[@R35]\]. The hypothesis that Chloroquine may also reduce atherosclerosis in humans is currently under investigation \[[@R36]\]. The mechanisms responsible for upregulation of genes involved in mitochondrial biogenesis are not evident in the current study; however, we did identify downregulation of the *UCP2* gene in AOD samples. The UCP2 protein belongs to a group of mitochondrial transporters that create proton leaks across the inner mitochondrial membrane, thus uncoupling respiration from ATP synthesis \[[@R37]\]. Previous studies provide evidence that uncoupling by UCP2 downregulates the production of reactive oxygen species (ROS) in endothelial and smooth muscle cells \[[@R38]-[@R42]\], whereas the UCP2 deficiency is associated with enhanced ROS production in the endothelium of the aorta \[[@R43]\]. Excessive ROS production is known to contribute to the oxidative damage of mitochondria that needs to be repaired to maintain intact cellular mitochondrial content \[[@R44]\]. This process is accomplished via mitophagy (autophagy), a selective elimination of malfunctioning mitochondria, which must be balanced by mitochondrial biogenesis to meet tissue energy requirements \[[@R45]\]. It is possible that UCP2 deficiency may, in fact, indirectly lead to increased mitochondrial biogenesis, explaining the upregulation of genes related to the metabolic and oxidative phosphorylation pathways in AOD. Pathways related to inflammation were less evident amongst differentially expressed genes in AOD samples. We did demonstrate the upregulation of a number of complement regulatory and effectors genes, such as complement regulatory protein *CD46*, complement factor H (*CFH*), and complement factor I (*CFI*) suggesting potential involvement of the classical complement activation pathway in AOD. The overexpression of the complement component 7 (*C7*) gene, a constituent of the membrane attack complex (MAC), may indicate the culmination of the alternative complement activation pathway in AOD. Findings are in line with previous studies that have suggested an important role for the complement system in mediating tissue injury and atherosclerosis after oxidative stress \[[@R46], [@R47]\].

Limitation of the study {#s3_3}
-----------------------

The current study has a number of limitations. The available sample size was relatively small especially for AOD although larger than any previously published microarrays using human aortic biopsies. In view of this limitation we sought to validate important findings in further groups of AAA and AOD biopsies. The assessment of independent samples helps to minimize the possibility that selection biases adversely affect the generalizability of the findings. Furthermore, we were able to obtain the aortic biopsies from advanced stage disease including AAAs measuring at least 50mm and patients needing aortic bypass for peripheral ischemia. Our findings therefore are difficult to relate to early stage vascular disease. The majority of available AAA and AOD biopsies were obtained from men limiting the relevance of our findings to AAA and AOD in women. Finally, the AOD patients were either younger (discovery group) or older (validation group) than their respective controls. In both particular comparisons of cases with controls, however, an important gene regulating mitochondrial biogenesis was found to be downregulated in AOD, suggesting that our findings are descriptive of the disease rather than age differences between cases and controls.

In conclusion, the current results demonstrate distinct gene expression profiles of AAA and AOD. The AAA transcriptome highlights an important mechanism controlling immune responses as opposed to the mitochondrial biogenesis pathways being predominantly associated with AOD pathology.

MATERIALS AND METHODS {#s4}
=====================

A detailed description of all methods is presented in the online data supplement.

Patients {#s4_1}
--------

Full thickness abdominal aortic specimens were obtained from 49 patients undergoing open surgery to treat AAA, 9 patients with AOD undergoing surgery to treat chronic lower limb ischemia, and 10 control individuals (discovery group, Table [1](#T1){ref-type="table"}). Maximum aortic diameter was 50-55mm (defined as small AAA) and 56-120mm (defined as large AAA) in 20 and 29 AAA subjects, respectively. Control full thickness abdominal aortic samples were obtained during kidney transplant (all from heart-beating, brain-dead donors). The study was approved by the ethics committees of the Townsville Hospital, James Cook University, Royal Brisbane and Women\'s Hospital, Medical Faculty at the Technical University Dresden, and Leiden University Medical Center and the protocol conformed to ethical guidelines of Declaration of Helsinki. All patients gave written informed consent.

Microarrays {#s4_2}
-----------

Microarrays were performed using the Illumina HumanHT-12v4 Expression BeadChip^®^ platform as previously described \[[@R16]\]. The microarray data can be obtained at the Gene Expression Omnibus (GEO) database repository (GSE57691; <http://www.ncbi.nlm.nih.gov/geo/info/linking.html>).

Analysis of array data {#s4_3}
----------------------

The raw data matrix extracted from BeadStudio was uploaded into the GeneSpring GX version 11.5.1 (Agilent Technologies Pty Ltd) software for downstream analysis as previously described \[[@R16]\]. We sought to identify genes with a 2-fold differential expression within the aortas of patients with small AAA, large AAA or AOD compared to donor abdominal aortas based on corrected p value \< 0.05 by the Benjamini Hochberg false discovery rate (FDR) method and determined by non-parametric Mann--Whitney U test. Genes showing ≥ 2-fold differences in expression between groups were considered to be significantly differentially expressed.

Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) {#s4_4}
--------------------------------------------------------------------------------

Using total RNA obtained from a further 29 patients with small AAAs (*n* = 6), large AAAs (*n* = 9) and AOD (*n* = 8), and another 6 organ donor biopsies (validation group, Table [1](#T1){ref-type="table"}) we assessed the validity of microarrays findings using qRT-PCR as described previously \[[@R16], [@R17]\]. Three genes associated with AAA (*CTLA4*, cytotoxic T-lymphocyte-associated protein 4; *NKTR*, natural killer cell triggering receptor; *CD8A*, CD8A molecule), and the uncoupling protein 2 gene (*UCP2*) associated with AOD were chosen for further assessment. Mann--Whitney U test was performed to identify differences in expression levels of selected genes between small AAA, or large AAA, or AOD and control biopsies. Data are reported as median and interquartile range. All computations were performed using the SPSS statistical package v.17.0.2. Statistical significance was defined at the conventional 5% level.

Immunohistochemistry {#s4_5}
--------------------

CD8 and CTLA4 proteins were immunohistochemically detected on 5-μm thick paraffin sections of AAA tissue taken from the maximally dilated aneurysm body as previously described \[[@R17]\].

SUPPLEMENTARY MATERIAL TABLES {#s5}
=============================

Funding from the Queensland Government, National Health and Medical Research Council (IDs 1020955, 1021416, 1063476 and 1000967) and Townsville Hospital Private Practice Trust supported this work. JG holds a Practitioner Fellowship from the National Health and Medical Research Council, Australia (ID 1019921) and a Senior Clinical Research Fellowship from the Queensland Government. EB was supported by the National Heart Foundation of Australia (G09B4339). IH is a recipient from the Technical University of Dresden (Frauenhabilitationsstipendium der Medizinischen Fakultät Dresden), Germany. GG received funding from W. L. Gore & Associates Deutschland GmbH and Vascutek Deutschland GmbH.

**CONFLICTS OF INTERESTS**

The author(s) declare that they have no conflict of interests.
